Valuation: Hikma Pharmaceuticals PLC

Capitalization 4.07B 3.47B 3.18B 3.01B 5.58B 389B 5.64B 37.9B 14.76B 185B 15.27B 14.94B 642B P/E ratio 2026 *
9.86x
P/E ratio 2027 * 8.89x
Enterprise value 5.46B 4.65B 4.27B 4.04B 7.49B 522B 7.56B 50.83B 19.79B 248B 20.47B 20.04B 861B EV / Sales 2026 *
1.57x
EV / Sales 2027 * 1.46x
Free-Float
64.47%
Yield 2026 *
4.53%
Yield 2027 * 4.79%
1 day+0.29%
1 week-1.64%
Current month+0.54%
1 month+6.39%
3 months-10.84%
6 months-11.85%
Current year-9.29%
1 week 1,399
Extreme 1399
1,451
1 month 1,311
Extreme 1311
1,451
Current year 1,187
Extreme 1187
1,691
1 year 1,187
Extreme 1187
2,164
3 years 1,187
Extreme 1187
2,360
5 years 1,174.5
Extreme 1174.5
2,703
10 years 814.2
Extreme 814.2
2,768
Manager TitleAgeSince
Chief Executive Officer 69 01/12/2025
Director of Finance/CFO - 26/02/2026
Compliance Officer - 01/01/2024
Director TitleAgeSince
Director/Board Member 68 01/05/2020
Chairman 63 26/02/2026
Director/Board Member 69 14/10/2005
Change 5d. change 1-year change 3-years change Capi.($)
+0.29%-1.64%-27.79%-23.92% 4.07B
+2.37%+0.10%+31.01%+127.85% 883B
+1.28%-0.57%+45.49%+39.48% 540B
+2.51%+0.85%+9.36%+41.26% 367B
+1.00%-1.00%+20.39%+10.73% 328B
-0.93%+0.41%+33.81%+13.52% 288B
+0.20%+0.45%+28.92%+25.59% 283B
+0.98%-0.69%+39.71%-4.07% 278B
+1.86%+3.31%-30.98%-47.90% 206B
+2.03%+2.03%+22.39%+44.36% 181B
Average +0.56%+0.90%+17.23%+22.69% 335.78B
Weighted average by Cap. +0.43%+0.61%+26.37%+47.92%

Financials

2026 *2027 *
Net sales 3.47B 2.96B 2.71B 2.57B 4.76B 332B 4.8B 32.3B 12.58B 157B 13.01B 12.74B 547B 3.63B 3.1B 2.84B 2.69B 4.99B 348B 5.03B 33.85B 13.18B 165B 13.63B 13.35B 573B
Net income 414M 353M 324M 307M 569M 39.67B 574M 3.86B 1.5B 18.81B 1.56B 1.52B 65.37B 454M 387M 355M 336M 623M 43.43B 629M 4.23B 1.65B 20.6B 1.7B 1.67B 71.57B
Net Debt 1.39B 1.18B 1.09B 1.03B 1.9B 133B 1.92B 12.92B 5.03B 62.98B 5.21B 5.1B 219B 1.23B 1.05B 963M 912M 1.69B 118B 1.71B 11.47B 4.47B 55.91B 4.62B 4.52B 194B
Logo Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC is a multinational pharmaceutical company engaged in the development, manufacturing and marketing of a broad range of generic, branded and non-licensed pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Generics. It supplies hospitals across its markets with generic and specialty injectable products, supported by its manufacturing facilities in the United States (US), Europe and Middle East/North Africa (MENA). It supplies branded generic and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. It supplies oral, respiratory and other generic and specialty products to the North American retail market. Its manufacturing facilities in the US supply generic and specialty products to the US and Canada markets across a broad range of therapeutic areas, including respiratory, oncology and pain management.
Employees
9,400
Date Price Change Volume
13/05/26 1,406.00 p +0.29% 115,544
12/05/26 1,402.00 p -1.75% 472,425
11/05/26 1,427.00 p +0.67% 425,392
08/05/26 1,417.50 p +0.50% 800,018
07/05/26 1,410.50 p -1.33% 803,093
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
18.93USD
Average target price
25.52USD
Spread / Average Target
+34.80%

Quarterly revenue - Rate of surprise